Owens Christopher E L, Tan Owen, Kuroiwa-Trzmielina Joice, Shrestha Rupendra N, O'Brien Tracey, Tyrrell Vanessa, Schofield Deborah J
Centre for Economic Impacts of Genomic Medicine, Macquarie Business School, Macquarie University, Sydney, NSW, Australia.
Children's Cancer Institute, Sydney, NSW, Australia.
NPJ Precis Oncol. 2024 Oct 5;8(1):224. doi: 10.1038/s41698-024-00711-w.
Embedding precision medicine in paediatric oncology shows promise to have a positive impact on how children with cancer will be treated in the future. While there are a number of studies of precision medicine in childhood cancer, there is limited evidence available on the cost of implementing the related testing. This is the first Australian study that systematically measures the cost of using precision medicine in the care of high-risk childhood cancers, through the Zero Childhood Cancer Precision Medicine Programme. In 2021 Australian dollars, the estimated costs inclusive of genomic and preclinical testing were: (A) $12,743 per patient for access; (B) $14,262 per identification of molecular cause; and (C) $21,769 per MTB recommendation. The information gained supports the understanding of the cost of reporting clinically significant outcomes relevant to the biology of the tumour, diagnosis, prognosis and potentially improving clinical management for a child.
将精准医疗应用于儿科肿瘤学有望对未来儿童癌症的治疗产生积极影响。虽然有多项关于儿童癌症精准医疗的研究，但关于实施相关检测的成本的现有证据有限。这是澳大利亚第一项通过零儿童癌症精准医疗计划系统测量在高危儿童癌症护理中使用精准医疗成本的研究。以2021年澳元计算，包括基因组和临床前检测在内的估计成本为：(A) 每位患者获取检测的成本为12,743澳元；(B) 每确定一个分子病因的成本为14,262澳元；(C) 每个多学科团队（MTB）建议的成本为21,769澳元。所获得的信息有助于理解报告与肿瘤生物学、诊断、预后相关的临床显著结果以及潜在改善儿童临床管理的成本。
